{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:29:21Z","timestamp":1784334561635,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2012M3A9B6055415"],"award-info":[{"award-number":["2012M3A9B6055415"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A2B4004618"],"award-info":[{"award-number":["2017R1A2B4004618"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A5A2015391"],"award-info":[{"award-number":["2017R1A5A2015391"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00774-017-0871-2","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T02:27:23Z","timestamp":1507775243000},"page":"537-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Bortezomib prevents ovariectomy-induced osteoporosis in mice by inhibiting osteoclast differentiation"],"prefix":"10.1007","volume":"36","author":[{"given":"Sung-Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9049-6908","authenticated-orcid":false,"given":"Youngkyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"871_CR1","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","volume":"289","author":"SL Teitelbaum","year":"2000","unstructured":"Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504\u20131508","journal-title":"Science"},{"key":"871_CR2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","volume":"7","author":"H Takayanagi","year":"2007","unstructured":"Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292\u2013304","journal-title":"Nat Rev Immunol"},{"key":"871_CR3","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s00018-005-5175-3","volume":"62","author":"F Elefteriou","year":"2005","unstructured":"Elefteriou F (2005) Neuronal signaling and the regulation of bone remodeling. Cell Mol Life Sci 62:2339\u20132349","journal-title":"Cell Mol Life Sci"},{"key":"871_CR4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S1043-2760(98)00005-8","volume":"9","author":"TJ Martin","year":"1998","unstructured":"Martin TJ, Udagawa N (1998) Hormonal regulation of osteoclast function. Trends Endocrinol Metab 9:6\u201312","journal-title":"Trends Endocrinol Metab"},{"key":"871_CR5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrendo.2011.146","volume":"8","author":"JS Chen","year":"2012","unstructured":"Chen JS, Sambrook PN (2012) Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol 8:81\u201391","journal-title":"Nat Rev Endocrinol"},{"key":"871_CR6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coms.2015.07.001","volume":"27","author":"S Weinerman","year":"2015","unstructured":"Weinerman S, Usera GL (2015) Antiresorptive therapies for osteoporosis. Oral Maxillofac Surg Clin N Am 27:555\u2013560","journal-title":"Oral Maxillofac Surg Clin N Am"},{"key":"871_CR7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/bonekey.2015.1","volume":"4","author":"BM Misof","year":"2015","unstructured":"Misof BM, Fratzl-Zelman N, Paschalis EP, Roschger P, Klaushofer K (2015) Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects. Bonekey Rep 4:634","journal-title":"Bonekey Rep"},{"key":"871_CR8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/bonekey.2014.13","volume":"3","author":"F Cosman","year":"2014","unstructured":"Cosman F (2014) Combination therapy for osteoporosis: a reappraisal. Bonekey Rep 3:518","journal-title":"Bonekey Rep"},{"key":"871_CR9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2265.2009.03541.x","volume":"71","author":"BL Clarke","year":"2009","unstructured":"Clarke BL (2009) New and emerging treatments for osteoporosis. Clin Endocrinol 71:309\u2013321","journal-title":"Clin Endocrinol"},{"key":"871_CR10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","volume":"11","author":"D Chen","year":"2011","unstructured":"Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP (2011) Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11:239\u2013253","journal-title":"Curr Cancer Drug Targets"},{"key":"871_CR11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.bbrc.2005.09.146","volume":"338","author":"U Heider","year":"2005","unstructured":"Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O (2005) Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 338:687\u2013693","journal-title":"Biochem Biophys Res Commun"},{"key":"871_CR12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.28481","volume":"120","author":"M Mohty","year":"2014","unstructured":"Mohty M, Malard F, Mohty B, Savani B, Moreau P, Terpos E (2014) The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer 120:618\u2013623","journal-title":"Cancer"},{"key":"871_CR13","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483\u20132494","journal-title":"N Engl J Med"},{"key":"871_CR14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/bonekey.2013.129","volume":"2","author":"E Terpos","year":"2013","unstructured":"Terpos E, Christoulas D (2013) Effects of proteasome inhibitors on bone cancer. Bonekey Rep 2:395","journal-title":"Bonekey Rep"},{"key":"871_CR15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ctrv.2011.12.007","volume":"38","author":"M Zangari","year":"2012","unstructured":"Zangari M, Terpos E, Zhan F, Tricot G (2012) Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev 38:968\u2013980","journal-title":"Cancer Treat Rev"},{"key":"871_CR16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/ejh.12069","volume":"90","author":"MF Kaiser","year":"2013","unstructured":"Kaiser MF, Heider U, Mieth M, Zang C, von Metzler I, Sezer O (2013) The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling. Eur J Haematol 90:263\u2013272","journal-title":"Eur J Haematol"},{"key":"871_CR17","first-page":"491","volume":"118","author":"S Mukherjee","year":"2008","unstructured":"Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T et al (2008) Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Investig 118:491\u2013504","journal-title":"J Clin Investig"},{"key":"871_CR18","first-page":"129","volume":"33","author":"S Munemasa","year":"2008","unstructured":"Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, Kubo T, Shimose S, Kimura A (2008) Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol 33:129\u2013136","journal-title":"Int J Oncol"},{"key":"871_CR19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","volume":"84","author":"A Pennisi","year":"2009","unstructured":"Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S (2009) The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 84:6\u201314","journal-title":"Am J Hematol"},{"key":"871_CR20","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","volume":"113","author":"YW Qiang","year":"2009","unstructured":"Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD Jr (2009) Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin\/TCF signaling. Blood 113:4319\u20134330","journal-title":"Blood"},{"key":"871_CR21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbrc.2014.04.044","volume":"447","author":"T Sanvoranart","year":"2014","unstructured":"Sanvoranart T, Supokawej A, Kheolamai P, Yaowalak U, Klincumhom N, Manochantr S, Wattanapanitch M, Issaragrisil S (2014) Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues. Biochem Biophys Res Commun 447:580\u2013585","journal-title":"Biochem Biophys Res Commun"},{"key":"871_CR22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2443.2012.01611.x","volume":"17","author":"M Uyama","year":"2012","unstructured":"Uyama M, Sato MM, Kawanami M, Tamura M (2012) Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib. Genes Cells 17:548\u2013558","journal-title":"Genes Cells"},{"key":"871_CR23","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1177\/0022034515592592","volume":"94","author":"YG Kim","year":"2015","unstructured":"Kim YG, Kang JH, Kim HJ, Kim HJ, Kim HH, Kim JY, Lee Y (2015) Bortezomib inhibits osteoclastogenesis and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption. J Dent Res 94:1243\u20131250","journal-title":"J Dent Res"},{"key":"871_CR24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394C(T) method. Methods 25:402\u2013408","journal-title":"Methods"},{"key":"871_CR25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1083\/jcb.124.6.1091","volume":"124","author":"P Reponen","year":"1994","unstructured":"Reponen P, Sahlberg C, Munaut C, Thesleff I, Tryggvason K (1994) High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 124:1091\u20131102","journal-title":"J Cell Biol"},{"key":"871_CR26","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.leukres.2008.02.019","volume":"32","author":"P Boissy","year":"2008","unstructured":"Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaisse JM (2008) Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res 32:1661\u20131668","journal-title":"Leuk Res"},{"key":"871_CR27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.leukres.2008.07.028","volume":"33","author":"H Hongming","year":"2009","unstructured":"Hongming H, Jian H (2009) Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk Res 33:115\u2013122","journal-title":"Leuk Res"},{"key":"871_CR28","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","volume":"21","author":"I Metzler von","year":"2007","unstructured":"von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, Kaiser M, Jakob C, Sterz J, Kleeberg L, Heider U, Sezer O (2007) Bortezomib inhibits human osteoclastogenesis. Leukemia 21:2025\u20132034","journal-title":"Leukemia"},{"key":"871_CR29","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1038\/cddis.2013.294","volume":"4","author":"V Khedgikar","year":"2013","unstructured":"Khedgikar V, Kushwaha P, Gautam J, Verma A, Changkija B, Kumar A, Sharma S, Nagar GK, Singh D, Trivedi PK, Sangwan NS, Mishra PR, Trivedi R (2013) Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone. Cell Death Dis 4:e778","journal-title":"Cell Death Dis"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-017-0871-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-017-0871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-017-0871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T21:03:18Z","timestamp":1535403798000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-017-0871-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1007\/s00774-017-0871-2","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]}}}